Clinical relevance of antibodies to HLA antigens undetectable by the standard complement-dependent cytotoxicity test

Transplant International

Volumn 16, Issue 12, 2003, Pages 872-878

  Slavcev, Antonij ^a   Lácha, Jiri ^a   Honsová, Eva ^a   Sajdlová, Helena ^a   Lodererová, Alena ^a   Vítko, Štefan ^a   Valhová, Šarka ^a   Stříž, Ilja ^a   Ivašková, Eva ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Antibodies; C4d; Crossmatch; Flow cytometry ELISA; HLA; Kidney transplantation

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ANTIBODY DETECTION; ARTICLE; CHRONIC DISEASE; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0348148839     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0642-y     Document Type: Article

References (36)

1. Pascual M, Theruvath T, Kawai T, Tolkoff RN, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. New Engl J Med 2002; 346:580.
2. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69:319.
3. Piazza A, Adorno D, Poggi E, et al. Flow cytometry crossmatch: a sensitive technique for assessment of acute rejection in renal transplantation. Transplant Proc 1998; 30:1769.
4. Christiaans MH, Overhof-de Roos R, Nieman F, van Hooff JP, van den Berg-Loonen EM. Donor-specific antibodies after transplantation by flow cytometry: relative change in fluorescence ratio most sensitive risk factor for graft survival. Transplantation 1998; 65:427.
5. Costa AN, Scolari MP, Iannelli S, et al. The presence of posttransplant HLA-specific IgG antibodies detected by enzyme-linked immunosorbent assay correlates with specific rejection pathologies. Transplantation 1997; 63:167.
6. Mauiyyedi S, Colvin RB: Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11:609.
7. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16:2058.
8. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.
9. Slavcev A, Ivasková E, Kalanin J, et al. Flow cytometry cross-match before kidney transplantation in relation to early postransplant rejection. Bone Marrow Transplant 1998; 22:S114, 1998.
10. Slavcev A, Lacha J, Sajdlova H, et al. Characterization of patient antibodies after kidney transplantation. Ann Transplant 2001; 6:12.
11. Martin S, Claas F. Antibodies and crossmatching for transplantation. In: Dyer PA, Middleton D eds. Histocompatibility Testing. Oxford, Oxford University Press, 1993:81.
12. Brown C, Navarette C. Screening for HLA-specific antibodies. In: Bidwell JL, Navarette C eds. Histocompatibility Testing. London, Imperial College Press, 2000:65.
13. Sridhar NR, Munda R, Balakrishnan K, First MR. Evaluation of flowcytometric crossmatching in renal allograft recipients. Nephron 1992; 62:262.
14. Gaston RS, Shroyer TW, Hudson SL, et al. Renal retransplantation: the role of race, quadruple immunosuppression, and the flow cytometry cross-match. Transplantation 1994; 57:47.
15. Nelson PW, Eschliman P, Shield CF, et al. Improved graft survival in cadaveric renal retransplantation by flow crossmatching. Arch Surg 1996; 131:599.
16. Mahoney RJ, Norman DJ, Colombe BW, Garovoy MR, Leeber DA. Identification of high- and low-risk second kidney grafts. Transplantation 1996; 61:1349.
17. Cook DJ, Fettouh HI, Gjertson DW, Cecka JM: Flow cytometry cross-matching (FCXM) in the UNOS Kidney Transplant Registry. Clin Transpl 1998; 413.
18. Bryan CF, Baier KA, Nelson PW, et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching. Transplantation 1998; 66:1827.
19. Christiaans MH, Overhof R, ten Haaft A, Nieman F, van Hooff JP, van den Berg-Loonen EM. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients. Transplantation 1996; 62:1341.
20. Kimball P, Rhodes C, King A, Fisher R, Ham J, Posner M. Flow cross-matching identifies patients at risk for postoperative elaboration of cytotoxic antibodies. Transplantation 1998; 65:444.
21. Scornik JC, Clapp W, Patton PR, et al. Outcome of kidney transplants in patients known to be flow cytometry crossmatch positive. Transplantation 2001; 71:1098.
22. Utzig MJ, Blumke M, Wolff Vorbeck G, Lang H, Kirste G. Flow cytometry cross-match: a method for predicting graft rejection. Transplantation 1997; 63:551.
23. O'Rourke RW, Osorio RW, Freise CE, et al. Flow cytometry crossmatching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants. Clin Transplant 2000; 14:167.
24. Karpinski M, Rush D, Jeffery J, et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001; 12:2807.
25. Schönemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance. Transplantation 1998; 65:1519.
26. Kotb M, Russell WC, Hathaway DK, Gaber LW, Gaber AO. The use of positive B cell flow cytometry crossmatch in predicting rejection among renal transplant recipients. Clin Transplant 1999; 13:83.
27. Piazza A, Borrelli L, Monaco PI, et al. Posttransplant donor-specific antibody characterization and kidney graft survival. Transpl Int 2000; 13:S439.
28. Supon P, Constantino D, Hao P, et al. Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 2001; 71:577.
29. Mahoney RJ, Taranto S, Edwards E. B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol 2002; 63:324.
30. Papassavas AC, Iniotaki-Theodoraki A, Boletis J, Kostakis A, Stavropoulos-Giokas C. Development of anti-HLA-antibodies against intra-CREG-mismatches in renal transplant recipients. Transplant Proc 1999; 31:757.
31. Worthington JE, Robson AJ, Sheldon S, Langton A, Martin S. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001; 62:1178.
32. Rebibou JM, Bittencourt MC, Ducloux D, et al. Anti-class II antibodies in kidney transplant patients. Transplant Proc 2000; 32:2748.
33. Susal C, Opelz G. Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 2002; 73:1269.
34. Gebel HM, Bray RA. Sensitization and sensitivity: defining the unsensitized patient. Transplantation 2000; 69:1370.
35. Christiaans MH, Nieman F, van Hooff JP, van den Berg Loonen EM. Detection of HLA class I and II antibodies by ELISA and complement-dependent cytotoxicity before and after transplantation. Transplantation 2000; 69:917.
36. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98:786.